Adis storms ahead in latest Impact Factor announcement

Adis Journals made impressive gains in the recent Journal Citation Reports® for 2012 unveiled by Thomson Reuters, in further affirmation of their focus on publishing high quality, clinically relevant content.

Of the publisher’s 19 core titles, 14 have Impact Factors, with an overall average of 3.107.


Drugs, the publisher’s flagship journal, increased its Impact Factor to 4.633, with Clinical Pharmacokinetics and Sports Medicine also seeing notable rises to 6.109 and 5.237 respectively.

Adis continues to boost its position as a leading publisher in Health Economics and Outcomes Research, with PharmacoEconomics maintaining its position as the number one journal in pharmacoeconomics and The Patient: Patient-Centered Outcomes Research, a quarterly journal that aims exclusively to examine the needs, values and role of the patient, seeing an astonishing year-on-year growth of 176%, taking its new Impact Factor to 1.565!

Adis strive to publish high-quality content that will enable you better therapeutic decisions. The journal portfolio contains a range of broad-scope and specialist titles with strong specialisms in pharmacoeconomics and clinical drug evaluation. By publishing a complementary blend of original research, independent Adis Drug Evaluations and invited reviews, they aim to provide an unparalleled evaluation of all the available evidence on new and established pharmacological interventions. All Adis journals are peer reviewed and now available on the SpringerLink and Springer for R&D platforms.